Vancomycin Global Market Report 2024

Vancomycin is a powerful antibiotic used against bacterial infections, particularly Gram-positive strains resistant to other antibiotics. It operates by impeding bacterial cell wall synthesis, halting bacterial growth.

The primary forms of vancomycin are injectable solutions and powder for injection. Injectable solutions are pre-mixed liquids for intravenous use, ensuring swift and effective treatment of severe infections by directly delivering the drug into the bloodstream. The routes of administration include intravenous and oral methods, targeting applications such as sepsis, lung and skin infections, colitis, and for preventative measures against infections.

The vancomycin market research report is one of a series of new reports that provides vancomycin market statistics, including vancomycin industry global market size, regional shares, competitors with a vancomycin market share, detailed vancomycin market segments, market trends, and opportunities, and any further data you may need to thrive in the vancomycin industry. This vancomycin research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The vancomycin market size has grown rapidly in recent years. It will grow from $0.74 billion in 2023 to $0.82 billion in 2024 at a compound annual growth rate (CAGR) of 11%. The historic growth of vancomycin usage can be attributed to several factors, including an increased focus on detecting and preventing infectious diseases, the implementation of government-funded programs for disease surveillance, a rise in global travel and trade leading to heightened infection risks, greater utilization in hospital settings for severe infections, and an overall increase in healthcare expenditure supporting antibiotic treatments.

The vancomycin market size is expected to see rapid growth in the next few years. It will grow to $1.26 billion in 2028 at a compound annual growth rate (CAGR) of 11.3%. The forecasted growth of vancomycin usage can be attributed to several trends and factors. These include the increasing emergence of novel pathogens, which necessitates the need for effective antibiotics such as vancomycin, a growing demand for rapid and on-site testing solutions to detect infections quickly and accurately, a heightened emphasis on early detection systems to prevent the spread of infections, and increased research and development activities in the field of infectious disease management. Additionally, major trends in the forecast period include advancements in diagnostic technologies such as miniaturization and portability of diagnostic devices, adoption of multiplex assays for detecting multiple pathogens simultaneously, integration of digital health solutions for efficient data management, utilization of next-generation sequencing (NGS) technologies for comprehensive pathogen identification, advancements in biosensor technologies for sensitive detection, and integration of AI and machine learning algorithms into diagnostic platforms for enhanced accuracy and efficiency.

The vancomycin market is poised for growth due to the increasing prevalence of infectious diseases caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites. Factors contributing to this rise include antimicrobial resistance, climate change, and population growth. Vancomycin plays a critical role in treating severe gram-positive bacterial infections, particularly resistant strains, following clinical guidelines and antimicrobial stewardship for optimal patient outcomes. For example, the global HIV/AIDS population exceeded 39 million in 2023, showing a 3.17% increase from 2020, as reported by UNAIDS. Additionally, tuberculosis (TB) cases in the US rose by 5.9% from 2021 to 2022, according to the Centers for Disease Control and Prevention.

Key players in the vancomycin market are actively developing innovative products such as anti-infective and anti-hypotensive medications to maintain their market position. Anti-infective medications target infections caused by various microorganisms, while anti-hypotensive medications are used to raise blood pressure in individuals with hypotension. For instance, Baxter International Inc. launched five injectable products in the US in April 2024, addressing anesthesia, pain management, and specialized therapies needs, demonstrating a commitment to improving patient outcomes.

In January 2023, Fairlong Capital LLC acquired DoseMeRx from Tabula Rasa HealthCare Group Inc., expanding its presence in healthcare technology with DoseMeRx's clinical decision support software for personalized dosing. DoseMeRx assists pharmacists and physicians in accurately tailoring doses of high-risk parenteral medications to individual patient needs.

Major companies operating in the vancomycin market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Siemens Healthineers AG, Becton Dickinson And Company, Quest Diagnostics Incorporated, Hologic Inc., bioMérieux SA, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Ortho Clinical Diagnostics Pvt. Ltd., DiaSorin SpA, Myriad Genetics Inc., Seegene Inc., ANI Pharmaceuticals Inc., Alvogen Inc., Biodesix Inc., Helix OpCo LLC, Inovio Pharmaceuticals Inc.

North America was the largest region in the vancomycin market in 2023. The regions covered in the vancomycin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the vancomycin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The vancomycin market consists of sales of intravenous (IV) formulations, compounded products, diagnostic kits and monitoring devices, therapeutic drug monitoring (TDM) kits, and diagnostic devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.